Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

Summary

To evaluate the preliminary activity and pharmacokinetics of 2 separate doses and schedules of orally administered Temsirolimus (CCI-779) given in combination with daily letrozole, compared to letrozole alone, in the treatment of locally advanced or metastatic breast cancer in postmenopausal women. All patients must be appropriate to receive endocrine therapy as treatment for advanced disease.

Timeline

Start

2002-12

Primary completion

2005-04

Completion

2009-10

Drugs

Indications